Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. Laboratory investigation

Journal of Neurosurgery

Volumn 112, Issue 1, 2010, Pages 33-42

  Ohba, Shigeo ^a   Hirose, Yuichi ^b   Yoshida, Kazunari ^a   Yazaki, Takahito ^a   Kawase, Takeshi ^a  

^a KEIO UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

17 (allylamino) 17 demethoxygeldanamycin; Akt; Glioma; Heat shock protein

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 25C; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; PROTEIN P53; RADICICOL; SURVIVIN; TANESPIMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLONOGENESIS; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CARMUSTINE; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DACARBAZINE; DRUG THERAPY, COMBINATION; FEMALE; GLIOMA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL;

EID: 75749117599     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.3.JNS081146     Document Type: Article

References (51)

1. Aligue R, Akhavan-Niak H, Russell P: A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J 13:6099-6106, 1994
2. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al: Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:8984-8995, 2003
3. Bobo RH, Laske DW, Akbasak A, Morisson PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076-2080, 1994
4. Bruce JN, Falavigna A, Johnson JP, Hall JS, Birch BD, Yoon JT, et al: Intracerebral clysis in a rat glioma model. Neurosurgery 46:683-691, 2000
5. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, et al: Enhanced tumor cell radiosensitivity and abroga tion of G2 and S phase arrest by the Hsp90 inhibitor 17-(di methylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 10:8077-8084, 2004
6. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55, 1984
7. Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, et al: Combination treatment with 17-N-allylation-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 63:8393-8399, 2003
8. Ferrarini M, Heltai S, Zocchi MR, Rugarli C: Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51:613-619, 1992
9. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, et al: Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 100:13791-13796, 2003
10. García-Morales P, Carrasco-García E, Ruiz-Rico P, Martínez-Mira R, Menéndez-Gutiérrez MP, Ferragut JA, et al: Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines. Oncogene 26:7185-7193, 2007
11. Grossman SA, Batara JF: Current management of glioblastoma multiforme. Semin Oncol 31:635-644, 2004
12. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
13. 2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma ells. Cancer Res 61:5843-5849, 2001
14. Hirose Y, Berger MS, Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963, 2001
15. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO: Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 65: 4861-4869, 2005
16. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO: The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 23:8306-8315, 2003
17. Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper RO: Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg 98:591-598, 2003
18. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN: Combined activation of Ras and Akt in neural progenitors induced glioblastoma formation in mice. Nat Genet 25:55-57, 2000
19. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al: A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 425:407-410, 2003
20. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, et al: Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22:7831-7841, 2002
21. Katayama M, Kawaguchi T, Berger MS, Pieper RO: DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14:548-558, 2007
22. Kuo PL, Hsu YL, Cho CY: Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 5: 3209-3221, 2006
23. Liang J, Slingerland JM: Multiple roles of the P13K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339-345, 2003
24. McIlwrath AJ, Brunton VG, Brown R: Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumor cells. Cancer Chemother Pharmacol 37:423-428, 1996
25. Munster PN, Basso A, Solit D, Norton L, Rosen N: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 7:2228-2236, 2001
26. Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, et al: Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95:472-479, 2001
27. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61, 2002
28. Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, et al: The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo. Anticancer Drugs 18:875-882, 2007
29. Nomura M, Nomura N, Newcomb EW, Lukyanov Y, Tamasdan C, Zagzag D: Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J Cell Physiol 201:374-384, 2004
30. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892-6899, 2004
31. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, et al: Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 5:1197-1208, 2006
32. Sato S, Fujita N, Tsuruo T: Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 97:10832-10837, 2000
33. Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H, et al: Interaction of radicicol with members of the heat shock protein 90 family of the molecular chaperones. Mol Endocrinol 13:1435-1448, 1999
34. Senju M, Sueoka N, Sato A, Iwanaga K, Sakao Y, Tomimitsu S, et al: Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25c and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 132:150-158, 2006
35. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumor to taxol. Cancer Res 63:2139-2144, 2003
36. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775-1782, 2007
37. Srethapakdi M, Liu F, Tavorath R, Rosen N: Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 60:3940-3946, 2000
38. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
39. Supko JG, Hickman RL, Grever MR, Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315, 1995
40. 1-deoxyguanosinyl)-ethan in DNA treated with N,N1-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 42:3102-3105, 1982
41. Van Meter TE, Broaddus WC, Cash D, Fillmore H: Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. Cancer 107:2446-2454, 2006
42. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ: Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 65:235-243, 2004
43. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184:39-51, 1995
44. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320, 2005
45. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, et al: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3:523-530, 1997
46. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5: 79-88, 2003
47. Whitesell L, Lindquist SL: Hsp90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772, 2005
48. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324-8328, 1994
49. Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, et al: Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 24:3697-3707, 2005
50. Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, Hait WN: Disruption of the EF-2 kinase/Hsp90 protein complex: A possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res 61:4010-4016, 2001
51. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, et al: Identification of new biomarkers for clinical trial of Hsp90 inhibitors. Mol Cancer Ther 5:1256-1264, 2006